“Fighting Antimicrobial Resistance with Rapid POC diagnostics”
Our point of care diagnostics platform NANOPLEX™ uses Receptor Mediating Sensing for rapid identification of bacterial infection.
“Around 700,000 people around the world die annually due to drug-resistant infections. If no action is taken, it has been estimated that drug-resistant infections will kill 10 million people a year by 2050”
Dame Sally Davies, UK Chief Medical Officer (AMR review)
FluoretiQ are addressing the steadily growing threat of antibiotic resistance with an easy-to-use diagnostic that is 200x faster than conventional microbiological testing.
FluoretiQ have developed NANOPLEX™- a rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes. NANOPLEX™ ensures that patients receive the most effective antibiotic treatment from the start.
NANOPLEX™ uses Receptor Mediating Sensing to fluorescently label bacterial proteins. Our probe library can currently identify 98% of bacterial species associated with uncomplicated Urinary Tract Infections (UTI).
Saving Time, Saving Money, Saving Lives.
Co-founders Neciah and Josephine Dorh were both celebrated in the 42 under 42 event hosted by Insider: South West. The event celebrates the strength of rising business leaders, showcasing innovation across the South West of England.
FluoretiQ is a recipient of ‘The people’s choice award’ as nominated by their peers at the Launch: Great West Awards. Launch: GW celebrates scientific and deep-tech innovation emerging from the South West of England.
FluoretiQ has been shortlisted in the ‘Best MedTech Startup’ category of the 2019 OBN Awards. The OBN awards celebrate innovation and achievement of its members in the Life Sciences Industry.
FluoretiQ is a finalist in the ‘Health’ category of the Royal Society of Chemistry’s Emerging Technologies competition. The Emerging Technologies Competition is hosted as part of the RSC’s Chemistry Means Business event for early stage companies with unique chemistry driven innovation.